Bio-Technology General Corp. announced Tuesday that it willmarket BioLon in the United Kingdom and Argentina throughInphomed Ltd. and Morrith S.A., respectively.
New York-based Bio-Technology General's product BioLon is aready-to-use syringe containing a one percent solution ofsodium hyaluronate for use in ophthalmic surgery proceduressuch as cataract removal and corneal grafts. BTG(NASDAQ:BTGC) developed and manufactures BioLon in its ownfacilities.
(c) 1997 American Health Consultants. All rights reserved.